Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Safety and Efficacy of Solifenacin With Oxybutynin for the Treatment of Overactive Bladder (VECTOR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 18 years and older.~* Overactive bladder symptoms for greater than or equal to 3 months and as documented in a 3-day patient diary following screening and preceding baseline visit: \> 1 urge episodes/24 hours (average); greater than or equal to 8 micturitions/24 hours (average)~Exclusion Criteria:~* Urinary tract infection, chronic inflammation such as interstitial cystitis and bladder stones~* Clinically significant outflow obstruction~* Uncontrolled narrow angle glaucoma, urinary, or gastric retention~* Severe renal or hepatic impairment~* Chronic severe constipation or history of diagnosed GI obstructive disease~* Significant stress incontinence or mixed stress/urge incontinence where stress is the predominant factor~* Diagnosis or history of neurogenic bladder~* History of bladder or pelvic cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Solifenacin (Type: EXPERIMENTAL): Solifenacin succinate: 5 mg tablets, taken orally, once daily
- Oxybutynin IR (Type: ACTIVE_COMPARATOR): Oxybutynin Immediate Release: 5 mg capsules, taken orally, 3 times a day

Based on this trial design, predict the completion outcome and termination type (if applicable).